Cite
FDA Withdraws Approval of Pepaxto in Multiple Myeloma.
MLA
Myshko, Denise. “FDA Withdraws Approval of Pepaxto in Multiple Myeloma.” Formulary Watch, Feb. 2024, p. 1. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=175681959&authtype=sso&custid=ns315887.
APA
Myshko, D. (2024). FDA Withdraws Approval of Pepaxto in Multiple Myeloma. Formulary Watch, 1.
Chicago
Myshko, Denise. 2024. “FDA Withdraws Approval of Pepaxto in Multiple Myeloma.” Formulary Watch, February, 1. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=175681959&authtype=sso&custid=ns315887.